Fabrazyme for Fabry Disease: Side Effects, Dosage, Warnings


Generic drug: agalsidase beta

Brand name: Fabrazyme

What is Fabrazyme (agalsidase beta), and how does it work?

Fabrazyme (agalsidase beta) for intravenous infusion is a man-made form of the naturally-occurring enzyme a-galactosidase A that is used in the treatment of Fabry disease.

What are the side effects of Fabrazyme?

Common side effects of Fabrazyme include signs of allergic reaction such as:

What is the dosage for Fabrazyme?

Recommended Dosage

  • The recommended dosage of Fabrazyme is 1 mg/kg body weight infused every two weeks as an intravenous infusion.
  • Infusion rate:
    • The initial intravenous infusion rate is 0.25 mg/min (15 mg/hour).
      Slow the infusion rate in the event of infusion-associated reactions.
    • For patients > 30 kg, after patient tolerance to the infusion is well established, increase the infusion rate in increments of 0.05 to 0.08 mg/min (increments of 3 to 5 mg/hour) with each subsequent infusion. The minimum infusion duration is 1.5 hours (based on individual patient tolerability).
    • For patients weighing < 30 kg, the maximum infusion rate is 0.25 mg/minute (15 mg/hour).
  • Because of the potential for severe infusion-associated reactions,
    appropriate medical support measures should be readily available when
    Fabrazyme is administered.
  • Administer antipyretics prior to infusion of Fabrazyme.
  • Rechallenge: Patients who have had a positive skin test to Fabrazyme or
    who have tested positive for anti-Fabrazyme IgE may be successfully
    rechallenged with Fabrazyme. The initial rechallenge administration should
    be a low dose at a lower infusion rate, e.g., ½ the therapeutic dose (0.5
    mg/kg) at 1/25 of the initial standard recommended rate (0.01 mg/min). Once
    a patient tolerates the infusion, the dose may be increased to reach the
    approved dose of 1 mg/kg and the infusion rate may be increased by slowly
    titrating upwards (doubled every 30 minutes up to a maximum rate of 0.25
    mg/minute), as tolerated.

What drugs interact with Fabrazyme?

No information provided

Is Fabrazyme safe to use while pregnant or breastfeeding?

  • Pregnant women and women of reproductive potential should be encouraged to enroll in the Fabry patient registry.
  • The registry will monitor the effect of Fabrazyme on pregnant women and their offspring.
  • For more information, visit www.registrynxt.com or call 1-800-745-4447, extension 15500.
  • There are no data on the presence of agalsidase beta in either human or animal milk, the effects of the drug on the breastfed infant, or on milk production.
  • The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Fabrazyme and any potential adverse effects on the breastfed child from Fabrazyme or from the underlying maternal condition.
  • Lactating women with Fabry disease treated with Fabrazyme should be encouraged to enroll in the Fabry registry.

Check Also

강남 셔츠룸 서울부장

강남 셔츠룸 매정한 나라에요 ㅋㅋㅋ 신규오픈 매장으로 설치 물품들이 많습니다. 역시 시부야 아니랄까봐 우리 나라 정서가 두 들겨야 흥이 더 나는듯 합니다. 아직 소버일때 우리 여자 예쁘니 직원들이랑 사진찍고 놀기  5~2배 정도 들었던것같아요 일환이었던 월성 원전 1호기 조기폐쇄에 대한 감사는 수위 조절이 실패해서 포기 햇엇드랫죠;; 대량 매출 가능한 입지라 확신합니다. 게임센터 규모도 장난 아니더라구요 차량…

Leave a Reply